Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
PLoS One ; 3(9): e3223, 2008 Sep 16.
Article in English | MEDLINE | ID: mdl-18795097

ABSTRACT

BACKGROUND: Hepatocyte Growth Factor (HGF) is a pleiotropic cytokine of mesenchymal origin that mediates a characteristic array of biological activities including cell proliferation, survival, motility and morphogenesis. Its high affinity receptor, the tyrosine kinase Met, is expressed by a wide range of tissues and can be activated by either paracrine or autocrine stimulation. Adult myogenic precursor cells, the so called satellite cells, express both HGF and Met. Following muscle injury, autocrine HGF-Met stimulation plays a key role in promoting activation and early division of satellite cells, but is shut off in a second phase to allow myogenic differentiation. In culture, HGF stimulation promotes proliferation of muscle precursors thereby inhibiting their differentiation. METHODOLOGY/PRINCIPAL FINDINGS: Magic-Factor 1 (Met-Activating Genetically Improved Chimeric Factor-1 or Magic-F1) is an HGF-derived, engineered protein that contains two Met-binding domains repeated in tandem. It has a reduced affinity for Met and, in contrast to HGF it elicits activation of the AKT but not the ERK signaling pathway. As a result, Magic-F1 is not mitogenic but conserves the ability to promote cell survival. Here we show that Magic-F1 protects myogenic precursors against apoptosis, thus increasing their fusion ability and enhancing muscular differentiation. Electrotransfer of Magic-F1 gene into adult mice promoted muscular hypertrophy and decreased myocyte apoptosis. Magic-F1 transgenic mice displayed constitutive muscular hypertrophy, improved running performance and accelerated muscle regeneration following injury. Crossing of Magic-F1 transgenic mice with alpha-sarcoglycan knock-out mice -a mouse model of muscular dystrophy- or adenovirus-mediated Magic-F1 gene delivery resulted in amelioration of the dystrophic phenotype as measured by both anatomical/histological analysis and functional tests. CONCLUSIONS/SIGNIFICANCE: Because of these features Magic-F1 represents a novel molecular tool to counteract muscle wasting in major muscular diseases such as cachexia or muscular dystrophy.


Subject(s)
Apoptosis , Muscles/pathology , Recombinant Proteins/metabolism , Animals , Cell Differentiation , Cell Proliferation , Cell Survival , Hypertrophy , Mice , Mice, Knockout , Mice, Transgenic , Models, Biological , Muscles/injuries , Phenotype , Proto-Oncogene Proteins c-met/metabolism , Sarcoglycans/metabolism , Stem Cells/metabolism
3.
Exp Cell Res ; 290(2): 207-16, 2003 Nov 01.
Article in English | MEDLINE | ID: mdl-14567980

ABSTRACT

We previously showed that clonable skeletal myogenic cells can be derived from the embryonic aorta but become very rare in the more mature and structured fetal aorta. The aim of this study was to investigate whether, during fetal and postnatal development, these myogenic progenitors progressively disappear or may rather associate with the microvascular district, being thus distributed to virtually all tissues. To test this hypothesis, we used F1 embryos (or mice) from a transgenic line expressing a striated muscle-specific reporter gene (LacZ) crossed with a transgenic line expressing a different endothelial-specific reporter genes (GFP). Endothelial cells were isolated from yolk sac (at E11) and lung (at E11, E17, P1, P10, and P60), two organs embryologically unrelated to paraxial mesoderm, rich in vessels, and devoid of skeletal muscle. Endothelial cells, purified by magnetic bead selection (CD31/PECAM-1(+)) or cell sorting (Tie2-GFP(+)) were then challenged for their skeletal myogenic potential in vitro and in vivo. The results demonstrated that both yolk sac and lung contain progenitor cells, which express endothelial markers and are endowed with a skeletal myogenic potential that they reveal when in the presence of differentiating myoblasts, in vitro, and regenerating muscle, in vivo. The number (or potency to generate skeletal muscle) of these vessels associated cells decreases rapidly with age and is very low in mature animals, possibly correlating with reduced regenerative capacity of adult mammalian tissues.


Subject(s)
Endothelium, Vascular/cytology , Lung/embryology , Muscle, Skeletal/cytology , Stem Cells/cytology , Yolk Sac/embryology , Aging , Animals , Animals, Newborn , Biomarkers/analysis , Cell Line , Endothelium, Vascular/metabolism , Female , Immunomagnetic Separation , Lung/metabolism , Mice , Mice, SCID , Mice, Transgenic , Muscle Development , Muscle, Skeletal/metabolism , Organ Culture Techniques , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Pregnancy , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/metabolism , Yolk Sac/metabolism
4.
Life Sci ; 73(15): 1973-83, 2003 Aug 29.
Article in English | MEDLINE | ID: mdl-12899922

ABSTRACT

Several researchers have recently shed new light upon the importance of extracellular nucleotides and nucleosides to stimulate cells growth. PDRN, a mixture of deoxyribonucleotides polymers of different lengths, has recently demonstrated to stimulate "in vitro" fibroblast proliferation and collagen production, probably stimulating the purinergic receptor system. In this work we evaluated the effects of PDRN on human cultured osteoblasts, focusing our attention on cell proliferation and alkaline phosphatase activity. PDRN at a concentration of 100 microg/ml induce an increase in osteoblasts growth after 6 days as compared to control (+21%). The addition of DMPX 50 microM and suramine (P2 inhibitor) 10 microM give different results: suramine has no significant effect, while DPMX reduce, even if partially, the PDRN induced cell growth. The alkaline phosphatase activity shows a gradual enhancement starting from day 0 to day 10, even if PDRN treated cells, examined at day 6, present a sensibly lower phosphatase activity when compared to controls. Our data demonstrate that PDRN acts as an osteoblast growth stimulator. Its action is partially due to a stimulation of the purinergic system mediated by A2 purinoreceptors, however we can not exclude the involvement of other mechanism like salvage pathway.


Subject(s)
Bone Regeneration/physiology , Osteoblasts/drug effects , Polydeoxyribonucleotides/pharmacology , Theobromine/analogs & derivatives , Alkaline Phosphatase/metabolism , Cell Division/drug effects , Cells, Cultured , Child, Preschool , Humans , Osteoblasts/enzymology , Purinergic P1 Receptor Antagonists , Purinergic P2 Receptor Antagonists , Suramin/pharmacology , Theobromine/pharmacology
5.
Development ; 129(11): 2773-83, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12015303

ABSTRACT

We have previously reported the origin of a class of skeletal myogenic cells from explants of dorsal aorta. This finding disagrees with the known origin of all skeletal muscle from somites and has therefore led us to investigate the in vivo origin of these cells and, moreover, whether their fate is restricted to skeletal muscle, as observed in vitro under the experimental conditions used. To address these issues, we grafted quail or mouse embryonic aorta into host chick embryos. Donor cells, initially incorporated into the host vessels, were later integrated into mesodermal tissues, including blood, cartilage, bone, smooth, skeletal and cardiac muscle. When expanded on a feeder layer of embryonic fibroblasts, the clonal progeny of a single cell from the mouse dorsal aorta acquired unlimited lifespan, expressed hemo-angioblastic markers (CD34, Flk1 and Kit) at both early and late passages, and maintained multipotency in culture or when transplanted into a chick embryo. We conclude that these newly identified vessel-associated stem cells, the meso-angioblasts, participate in postembryonic development of the mesoderm, and we speculate that postnatal mesodermal stem cells may be derived from a vascular developmental origin.


Subject(s)
Aorta/embryology , Mesoderm/cytology , Muscle, Smooth, Vascular/embryology , Animals , Aorta/cytology , Cell Culture Techniques , Cell Differentiation , Cells, Cultured , Coturnix , Mice , Mice, Transgenic , Muscle, Smooth, Vascular/cytology , Reverse Transcriptase Polymerase Chain Reaction
6.
Ann Anat ; 184(2): 153-7, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11936195

ABSTRACT

In the present study we describe a method for the histochemical demonstration of bacterial beta-D-galactosidase activity on skeletal muscle tissue processed for light and transmission electron microscopy. Hence allowing this enzyme to be accurately detected, bacterial beta-galactosidase expression was studied in transgenic mouse where the enzyme, with the nuclear localization signal (nlacZ), is under the transcriptional control of the striated muscle-specific promoter MLC3F. The chromogenic substrate, 5-bromo-3-indolyl-beta-D-galactopyranoside (Bluo-Gal), was used both to recognize labelled myofibers, and beta-gal positive organelles inside single myofibers. Moreover, because the preservation of enzyme is highly dependent on tissue fixation, we developed a suitable fixation solution allowing good preservation of both tissue and enzymatic activity. This was achieved by briefly fixing tissue (3 hours) in glutaraldehyde (2.5%) and paraformaldehyde (1%) in combination. This method should be taken into consideration when studying the gene therapy of muscle diseases because it is sensitive, inexpensive and not time consuming.


Subject(s)
Muscle, Skeletal/enzymology , beta-Galactosidase/metabolism , Animals , Escherichia coli/enzymology , Genes, Reporter , Histocytochemistry , Mice , Mice, Transgenic , Microscopy, Electron , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Skeletal/ultrastructure , Muscle, Skeletal/cytology , Muscle, Skeletal/ultrastructure , Myosin Light Chains/genetics , Transcription, Genetic , beta-Galactosidase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...